Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Stewart

Showing results (71-80 of 208) with videos related to

Pageof 21
Sort By:
Blood|July 20, 2006
MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myelomaEsther Masih-Khan, Suzanne Trudel, Carla Heise, et al.
British Journal of Haematology|November 28, 2008
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access programJoseph R Mikhael, Andrew R Belch, H Miles Prince, et al.
Journal of the American Society of Nephrology : JASN|July 31, 2004
Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusionEdward J Sharples, Nimesh Patel, Paul Brown, et al.
Molecular Cancer Therapeutics|June 19, 2007
Determinants of sensitivity to lovastatin-induced apoptosis in multiple myelomaW Wei-Lynn Wong, James W Clendening, Anna Martirosyan, et al.
BMC Cancer|May 5, 2016
Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survivalQinqin Xu, Yue-xian Hou, Paul Langlais, et al.
Blood|February 4, 2011
RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5Yuan Xiao Zhu, Rodger Tiedemann, Chang-Xin Shi, et al.
Molecular Cancer Therapeutics|September 30, 2017
CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple MyelomaChang-Xin Shi, K Martin Kortüm, Yuan Xiao Zhu, et al.
British Journal of Haematology|August 1, 2012
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomibRavi Vij, David S Siegel, Sundar Jagannath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplantA Keith Stewart, Christine I Chen, Kang Howson-Jan, et al.
Blood|December 29, 2016
Multiple myeloma cells' capacity to decompose H<sub>2</sub>O<sub>2</sub> determines lenalidomide sensitivitySinto Sebastian, Yuan X Zhu, Esteban Braggio, et al.
Pageof 21

Showing results (71-80 of 208) with videos related to

Sort By:
Pageof 21
Blood|July 20, 2006
MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myelomaEsther Masih-Khan, Suzanne Trudel, Carla Heise, et al.
British Journal of Haematology|November 28, 2008
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access programJoseph R Mikhael, Andrew R Belch, H Miles Prince, et al.
Journal of the American Society of Nephrology : JASN|July 31, 2004
Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusionEdward J Sharples, Nimesh Patel, Paul Brown, et al.
Molecular Cancer Therapeutics|June 19, 2007
Determinants of sensitivity to lovastatin-induced apoptosis in multiple myelomaW Wei-Lynn Wong, James W Clendening, Anna Martirosyan, et al.
BMC Cancer|May 5, 2016
Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survivalQinqin Xu, Yue-xian Hou, Paul Langlais, et al.
Blood|February 4, 2011
RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5Yuan Xiao Zhu, Rodger Tiedemann, Chang-Xin Shi, et al.
Molecular Cancer Therapeutics|September 30, 2017
CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple MyelomaChang-Xin Shi, K Martin Kortüm, Yuan Xiao Zhu, et al.
British Journal of Haematology|August 1, 2012
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomibRavi Vij, David S Siegel, Sundar Jagannath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplantA Keith Stewart, Christine I Chen, Kang Howson-Jan, et al.
Blood|December 29, 2016
Multiple myeloma cells' capacity to decompose H<sub>2</sub>O<sub>2</sub> determines lenalidomide sensitivitySinto Sebastian, Yuan X Zhu, Esteban Braggio, et al.
Pageof 21